Please Select Year
Advanced Accelerator Applications to Build Targeted RadioLigand Therapy Production Facility in Indianapolis
Jun 30, 2020
Advanced Accelerator Applications Announces Start of Phase III Study Investigating Radioligand Therapy Lutathera® as First-Line Treatment in Patients with Advanced GEP-NETs
Mar 25, 2020
Advanced Accelerator Applications Announces State of Israel Ministry of Health Approval for Lutathera®, in the Treatment of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Jul 29, 2019
Advanced Accelerator Applications Receives Positive CHMP Opinion for LysaKare® for Reduction of Kidney Exposure to Radiation During Peptide Receptor Radionuclide Therapy with Lutetium (177Lu) Oxodotreotide (Lutathera®)
Jun 5, 2019
Advanced Accelerator Applications Announces Health Canada Approval for Lutathera™, a Treatment for Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Feb 7, 2019
Advanced Accelerator Applications signs exclusive option and license agreement with FUJIFILM Toyama Chemical to develop and commercialize radiolabeled FF-10158 for oncology indications
Dec 3, 2018
Novartis announces presentation of new Lutathera® NETTER-1 data at ESMO demonstrating significant improvement in PFS regardless of baseline liver tumor burden
Oct 19, 2018
Advanced Accelerator Applications Announces First Patients Dosed in Two Clinical Studies with PSMA-R2 for Prostate Cancer – Second Theragnostic Program for Oncology Enters the Clinic
Jun 22, 2018
Novartis announces JCO publication of Lutathera® NETTER-1 data showing significantly longer time to deterioration of key quality of life measures in patients with progressive midgut NETs
Jun 7, 2018
Advanced Accelerator Applications Signs Exclusive License Agreement with Cancer Targeted Technology to Develop CTT1057, an F-18 Labeled PSMA Ligand for Diagnostic Applications in Prostate Cancer
Feb 12, 2018
...
Media Contacts
Rachel Levine
Global Head of Communications and Patient Advocacy
rachel.levine@adacap.com
+1-917-375-2935
Veronique Mermet
Global Communications Specialist
info@adacap.com
+33 (0)4 50 99 30 70